PXD014234 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma |
Description | The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. IBL-302 was more effective than single PI3K inhibition in vitro and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N-Myc protein levels. IBL-302 further enhanced the effect of the common cytotoxic chemotherapies cisplatin, doxorubicin, and etoposide. Global genome, proteome and phospho-proteome analyses identified crucial biological processes, including cell motility and apoptosis, targeted by IBL-302 treatment. While IBL-302 treatment alone reduced tumor growth in vivo, combination therapy with low-dose cisplatin inhibited neuroblastoma PDX growth. Complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition has the potential to improve clinical outcomes and reduce severe late effects in children with high-risk neuroblastoma. |
HostingRepository | PRIDE |
AnnounceDate | 2019-07-11 |
AnnouncementXML | Submission_2019-07-18_00:47:01.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Charlotte Welinder |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | phosphorylated residue; acetylated residue; monohydroxylated residue |
Instrument | Q Exactive |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2019-06-12 07:57:30 | ID requested | |
1 | 2019-07-11 05:28:03 | announced | |
⏵ 2 | 2019-07-18 00:47:02 | announced | Updated publication reference for PubMed record(s): 31310053. |
Publication List
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D, Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mol Med, 11(8):e10058(2019) [pubmed] |
Keyword List
ProteomeXchange project tag: Cancer (B/D-HPP), Biology/Disease-Driven Human Proteome Project (B/D-HPP), Human Proteome Project |
submitter keyword: Cisplatin, IBL-302, Neuroblastoma, Multikinase inhibition, PI3K, LC-MS/MS |
Contact List
Charlotte Welinder |
contact affiliation | Division of Oncology and Pathology, Dept. of Clinical Sciences Lund, Lund University, Lund, Sweden |
contact email | charlotte.welinder@med.lu.se |
lab head | |
Charlotte Welinder |
contact affiliation | Dept. of Oncology, Clinical Sciences, Lund University, 221 85 Lund, Sweden |
contact email | charlotte.welinder@med.lu.se |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014234 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD014234
- Label: PRIDE project
- Name: Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma